Miniatura

Fitxers

691359.pdf (2.82 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2019-03-07

Llicència de publicació

cc by (c) Vink et al., 2019
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/172559

Immunogenicity and safety of adjuvanted recombinant zoster vaccine in chronically immunosuppresed adults following renal transplant: A phase III, randomized clinical trial

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1093/cid/ciz177

Resum

Background: The incidence of herpes zoster is up to 9 times higher in immunosuppressed solid organ transplant recipients than in the general population. We investigated immunogenicity and safety of an adjuvanted recombinant zoster vaccine (RZV) in renal transplant (RT) recipients ≥18 years of age receiving daily immunosuppressive therapy. Methods: In this phase III, randomized (1:1), observer-blind, multicenter trial (NCT02058589), RT recipients were enrolled and received 2 doses of RZV or Placebo 1-2 months (M) apart 4-18M post-transplant. Anti-glycoprotein E (gE) antibody concentrations, gE-specific CD4 T-cell frequencies, and vaccine response rates were assessed at 1M post-dose 1, and 1M and 12M post-dose 2. Solicited and unsolicited adverse events (AEs) were recorded for 7 and 30 days post-each dose, respectively. Solicited general symptoms and unsolicited AEs were also collected 7 days before first vaccination. Serious AEs (including biopsy-proven allograft rejections) and potential immune-mediated diseases (pIMDs) were recorded up to 12M post-dose 2. Results: 264 participants (RZV: 132; Placebo: 132) were enrolled between March 2014 and April 2017. gE-specific humoral and cell-mediated immune responses were higher in RZV than placebo recipients across post-vaccination time points and persisted above pre-vaccination baseline 12M post-dose 2. Local AEs were reported more frequently by RZV than placebo recipients. Overall occurrences of renal function changes, rejections, unsolicited AEs, SAEs, and pIMDs were similar between groups. Conclusions: RZV was immunogenic in chronically immunosuppressed RT recipients. Immunogenicity persisted through 12M post-vaccination. No safety concerns arose.

Matèries

Herpes zòster, Trasplantament renal, Immunosupressors

Matèries (anglès)

Shingles (Disease), Kidney transplantation, Immunosupressive agents

Citació

Col·leccions

Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

VINK, Peter, RAMON TORRELL, Josep m. (josep maria), SÁNCHEZ FRUCTUOSO, Ana, KIM, Sung-joo, KIM, Sang-il, ZALTZMAN, Jeff, ORTIZ, Fernanda, CAMPISTOL PLANA, Josep m., FERNANDEZ RODRIGUEZ, Ana maria, REBOLLO RODRIGO, Henar, CAMPINS MARTÍ, Magda, PEREZ, Rafael, GONZÁLEZ RONCERO, Francisco manuel, KUMAR, Deepali, CHIANG, Jen, DOUCETTE, Karen, PIPELEERS, Lissa, AGÜERA MORALES, Maria luisa, RODRIGUEZ-FERRERO, Maria luisa, SECCHI, Antonio, MCNEIL, Shelly a., CAMPORA, Laura, PAOLO, Emmanuel di, IDRISSI, Mohamed el, LÓPEZ-FAUQUED, Marta, SALAUN, Bruno, HEINEMAN, Thomas c., OOSTVOGELS, Lidia, Z-041 Study Group. Immunogenicity and safety of adjuvanted recombinant zoster vaccine in chronically immunosuppresed adults following renal transplant: A phase III, randomized clinical trial. _Clinical Infectious Diseases_. 2019. Vol. 70, núm. 2, pàgs. 181-190. [consulta: 23 de gener de 2026]. ISSN: 1058-4838. [Disponible a: https://hdl.handle.net/2445/172559]

Exportar metadades

JSON - METS

Compartir registre